Akari Therapeutics Secures Patent Protection In India for PH1, Its Novel Immuno-Oncology Antibody Drug Conjugate (ADC) Payload, Expanding Global IP Estate

Akari Therapeutics, Plc, a biotechnology company focused on developing innovative immuno-oncology antibody-drug conjugates (ADCs) for cancer treatment, has announced that Intellectual Property India has granted Patent No. 562,919, titled “Thailanstatin Analogs.” This newly issued patent provides protection for the company’s proprietary PH1 payload, as well as its cleavable and non-cleavable linker technologies and ADC platform, all of which have potential applications across a broad range of cancer targets.

The granted patent in India is part of a broader intellectual property strategy and is a divisional patent based on Akari’s existing research and development portfolio related to the PH1 toxin. It adds to a growing list of patent protections, including previously granted U.S. patents (US 10,815,246 B2, US 10,301,319 B2, and US 11,691,982 B2). Internationally, the patent family linked to PCT/US2018/051721 was also granted in China in August 2023 and in Israel in September 2023. Additional patent applications from this family are under review in various other regions, including Brazil, Canada, European Patent Organisation member countries, Hong Kong, Japan, New Zealand, Singapore, and South Africa.

Abizer Gaslightwala, President and CEO of Akari Therapeutics, mentioned, “We believe our innovative ADC payload PH1 has the potential to provide therapies that disrupt cellular function, trigger cancer cell death and most importantly, enhance the immune system to fight cancer beyond the cells targeted by the ADC molecule. The issuance of this patent further strengthens our global intellectual property estate and importantly, provides additional patent protection around our CMC manufacturing activities for this PH1 payload and related analogs. Importantly, as cancer rates and diagnosis continue to rise significantly in India, we believe the need for innovative cancer therapies continue to increase. We are pleased to bolster our intellectual property portfolio to include this key market for future opportunities to potentially help cancer patients with our immuno-oncology ADCs.”

Akari is using its proprietary PH1-based payload platform to advance a pipeline of novel ADC candidates aimed at diverse tumor types. These candidates are designed to deliver highly potent tumor-killing agents while also activating the immune system, offering the potential for deep and sustained therapeutic responses. Preclinical studies have shown encouraging results, highlighting the platform’s ability to target cancer cells effectively and stimulate a robust immune response. The company’s goal is to develop ADC therapies that could be first-in-class or best-in-class in the immuno-oncology field.